ID   PC3/DX
AC   CVCL_C3M5
DR   Wikidata; Q116050111
RX   DOI=10.29228/jrp.195;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0035 ! PC-3
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   DOI=10.29228/jrp.195;
RA   Acidereli H., Cevik O.;
RT   "Investigation of the effects of bicalutamide and TRAIL signaling
RT   mechanism on docetaxel resistant prostate cancer cells.";
RL   J. Res. Pharm. 26:980-991(2022).
//